重组人血管内皮抑制素对肝动脉化疗栓塞术后患者细胞免疫及生活质量的影响

Effect of Recombinant Human Endostatin on Cell Immunity and Life Quality of Patients with Transcatheter Arterial Chemoembolization

目的:探讨重组人血管内皮抑制素联合肝动脉化疗栓塞术(TACE)对原发性肝癌患者的临床效果。方法:选取2012年12月-2014年12月本院收治的原发性肝癌患者120例作为研究对象,随机分为对照组和观察组,每组60例。对照组采用TACE治疗,观察组采用重组人血管内皮抑制素联合TACE治疗,比较两组患者临床疗效、免疫功能及生活质量改善情况。结果:观察组临床治疗有效率为71.67%,疾病控制率为90.00%,明显高于对照组的45.00%和63.33%,比较差异均有统计学意义(P<0.01);对照组CD3^+、CD4^+、CD4^+/CD8^+水平较治疗前下降,而观察组CD3^+、CD4^+、CD4^+/CD8^+水平较治疗前升高,且观察组高于对照组,比较差异均有统计学意义(P<0.05);对照组Ig A、Ig G、Ig M较治疗前下降,而观察组较治疗前升高,且观察组高于对照组,比较差异均有统计学意义(P<0.05);观察组生存质量有效率为86.67%,高于对照组的65.00%,比较差异有统计学意义(P<0.05)。结论:在TACE术中联用重组人血管内皮抑制素能够提高原发性肝癌患者的治疗效果、增强免疫能力及提高生活质量。

Objective：To investigate the clinical effect of Recombinant Human Endostatin combined with transcatheter arterial chemoembolization in patients with primary hepatic carcinoma.Method：From December 2012 to December 2014,120 patients with primary liver cancer in our hospital were randomly divided into the control group and the observation group,each group had 60 cases.The control group was treated with TACE,the observation group was treated with Recombinant Human Endostatin combined with TACE.The clinical efficacy,immune function and quality of life in two groups were compared.Result：The clinical effective rate of the observation group was 71.67% and the disease control rate was 90.00%,were significantly higher than 45.00% and 63.33% of the control group,the differences were statistically significant（P〈0.01）.The levels of CD3＋、CD4＋、CD4＋/CD8＋ were decreased compared with before treatment in the control group,while the levels of CD3＋、CD4＋、CD4＋/CD8＋ were higher than before treatment in the observation group,and the observation group was higher than those of the control group,the differences were statistically significant（P〈0.05）. The control group Ig A,Ig G,Ig M decreased than before treatment and the observation group was higher than before treatment,the observation group was higher than the control group,the differences were statistically significant（P〈0.05）.The survival rate of the observation group was 86.67%,higher than 65.00% of the control group,the difference was statistically significant（P〈0.05）.Conclusion：TACE combined with Recombinant Human Endostatin can improve therapeutic effect of patients with primary liver cancer,enhance the immune ability and improve the quality of life.